vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and LATTICE SEMICONDUCTOR CORP (LSCC). Click either name above to swap in a different company.

LATTICE SEMICONDUCTOR CORP is the larger business by last-quarter revenue ($145.8M vs $77.6M, roughly 1.9× Bioceres Crop Solutions Corp.). LATTICE SEMICONDUCTOR CORP runs the higher net margin — -5.2% vs -9.6%, a 4.4% gap on every dollar of revenue. On growth, LATTICE SEMICONDUCTOR CORP posted the faster year-over-year revenue change (9.3% vs -16.8%). Over the past eight quarters, LATTICE SEMICONDUCTOR CORP's revenue compounded faster (8.4% CAGR vs -8.4%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

Lattice Semiconductor Corporation is an American semiconductor company specializing in the design and manufacturing of low power field-programmable gate arrays (FPGAs). Headquartered in the Silicon Forest area of Hillsboro, Oregon, the company also has operations in San Jose, Calif., Shanghai, Manila, Penang, and Singapore. Lattice Semiconductor has more than 1000 employees and an annual revenue of more than $660 million as of 2022. The company was founded in 1983 and went public in 1989. It ...

BIOX vs LSCC — Head-to-Head

Bigger by revenue
LSCC
LSCC
1.9× larger
LSCC
$145.8M
$77.6M
BIOX
Growing faster (revenue YoY)
LSCC
LSCC
+26.1% gap
LSCC
9.3%
-16.8%
BIOX
Higher net margin
LSCC
LSCC
4.4% more per $
LSCC
-5.2%
-9.6%
BIOX
Faster 2-yr revenue CAGR
LSCC
LSCC
Annualised
LSCC
8.4%
-8.4%
BIOX

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
BIOX
BIOX
LSCC
LSCC
Revenue
$77.6M
$145.8M
Net Profit
$-7.4M
$-7.6M
Gross Margin
46.8%
68.5%
Operating Margin
9.3%
30.7%
Net Margin
-9.6%
-5.2%
Revenue YoY
-16.8%
9.3%
Net Profit YoY
-20.2%
14.6%
EPS (diluted)
$-0.12
$-0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
LSCC
LSCC
Q1 26
$145.8M
Q3 25
$77.6M
$133.3M
Q2 25
$124.0M
Q1 25
$60.6M
$120.2M
Q4 24
$98.8M
$117.4M
Q3 24
$93.3M
$127.1M
Q2 24
$124.1M
Q1 24
$84.0M
Net Profit
BIOX
BIOX
LSCC
LSCC
Q1 26
$-7.6M
Q3 25
$-7.4M
$2.8M
Q2 25
$2.9M
Q1 25
$-1.6M
$5.0M
Q4 24
$605.2K
$16.5M
Q3 24
$-6.2M
$7.2M
Q2 24
$22.6M
Q1 24
$9.8M
Gross Margin
BIOX
BIOX
LSCC
LSCC
Q1 26
68.5%
Q3 25
46.8%
67.9%
Q2 25
68.4%
Q1 25
39.4%
68.0%
Q4 24
42.0%
61.1%
Q3 24
40.2%
69.0%
Q2 24
68.3%
Q1 24
50.8%
Operating Margin
BIOX
BIOX
LSCC
LSCC
Q1 26
0.7%
Q3 25
9.3%
-1.2%
Q2 25
3.8%
Q1 25
1.5%
5.8%
Q4 24
14.5%
-10.4%
Q3 24
2.5%
5.9%
Q2 24
18.2%
Q1 24
15.7%
Net Margin
BIOX
BIOX
LSCC
LSCC
Q1 26
-5.2%
Q3 25
-9.6%
2.1%
Q2 25
2.3%
Q1 25
-2.6%
4.2%
Q4 24
0.6%
14.1%
Q3 24
-6.6%
5.7%
Q2 24
18.2%
Q1 24
11.6%
EPS (diluted)
BIOX
BIOX
LSCC
LSCC
Q1 26
$-0.06
Q3 25
$-0.12
$0.02
Q2 25
$0.02
Q1 25
$-0.02
$0.04
Q4 24
$0.00
$0.12
Q3 24
$-0.10
$0.05
Q2 24
$0.16
Q1 24
$0.14

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
LSCC
LSCC
Cash + ST InvestmentsLiquidity on hand
$15.5M
$133.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$288.3M
$714.1M
Total Assets
$734.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
LSCC
LSCC
Q1 26
$133.9M
Q3 25
$15.5M
$117.9M
Q2 25
$107.2M
Q1 25
$38.5M
$127.6M
Q4 24
$29.2M
$136.3M
Q3 24
$32.3M
$124.3M
Q2 24
$109.2M
Q1 24
$16.4M
Stockholders' Equity
BIOX
BIOX
LSCC
LSCC
Q1 26
$714.1M
Q3 25
$288.3M
$706.4M
Q2 25
$687.0M
Q1 25
$345.0M
$707.9M
Q4 24
$346.3M
$710.9M
Q3 24
$346.0M
$703.5M
Q2 24
$698.8M
Q1 24
$348.5M
Total Assets
BIOX
BIOX
LSCC
LSCC
Q1 26
$883.1M
Q3 25
$734.9M
$844.4M
Q2 25
$808.6M
Q1 25
$798.2M
$823.6M
Q4 24
$835.2M
$843.9M
Q3 24
$827.3M
$853.7M
Q2 24
$827.5M
Q1 24
$836.1M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
LSCC
LSCC
Operating Cash FlowLast quarter
$14.4M
$57.6M
Free Cash FlowOCF − Capex
$44.0M
FCF MarginFCF / Revenue
30.2%
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$153.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
LSCC
LSCC
Q1 26
$57.6M
Q3 25
$14.4M
$47.1M
Q2 25
$38.5M
Q1 25
$23.3M
$31.9M
Q4 24
$-5.4M
$45.4M
Q3 24
$5.2M
$44.0M
Q2 24
$21.9M
Q1 24
$-17.4M
Free Cash Flow
BIOX
BIOX
LSCC
LSCC
Q1 26
$44.0M
Q3 25
$34.0M
Q2 25
$31.3M
Q1 25
$23.3M
Q4 24
$39.7M
Q3 24
$39.4M
Q2 24
$14.8M
Q1 24
FCF Margin
BIOX
BIOX
LSCC
LSCC
Q1 26
30.2%
Q3 25
25.5%
Q2 25
25.2%
Q1 25
19.4%
Q4 24
33.8%
Q3 24
31.0%
Q2 24
11.9%
Q1 24
Capex Intensity
BIOX
BIOX
LSCC
LSCC
Q1 26
9.3%
Q3 25
9.8%
Q2 25
5.8%
Q1 25
7.2%
Q4 24
4.9%
Q3 24
3.7%
Q2 24
5.8%
Q1 24
Cash Conversion
BIOX
BIOX
LSCC
LSCC
Q1 26
Q3 25
16.86×
Q2 25
13.23×
Q1 25
6.35×
Q4 24
-8.85×
2.75×
Q3 24
6.12×
Q2 24
0.97×
Q1 24
-1.78×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons